Propanc Biopharma Files 8-K: Material Agreement, Debt, Equity Sales
Ticker: PPCB · Form: 8-K · Filed: Aug 15, 2024 · CIK: 1517681
| Field | Detail |
|---|---|
| Company | Propanc Biopharma, Inc. (PPCB) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $33,000, $30,000, $0.0017, $0.0014, $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, debt, equity-sale
TL;DR
Propanc Biopharma inked a deal, took on debt, and sold stock. Big moves ahead.
AI Summary
Propanc Biopharma, Inc. announced on August 9, 2024, that it entered into a material definitive agreement. The company also disclosed the creation of a direct financial obligation and unregistered sales of equity securities. The filing details financial statements and exhibits related to these events.
Why It Matters
This filing indicates significant financial activities for Propanc Biopharma, including new obligations and equity transactions, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, direct financial obligations, and unregistered sales of equity, all of which can introduce financial risks and uncertainties.
Key Players & Entities
- Propanc Biopharma, Inc. (company) — Registrant
- August 9, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 000-54878 (filing_id) — SEC File Number
FAQ
What is the nature of the material definitive agreement entered into by Propanc Biopharma?
The filing states that Propanc Biopharma, Inc. entered into a material definitive agreement, but the specific details of this agreement are not provided in the summary text.
What type of direct financial obligation was created by Propanc Biopharma?
The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement of a registrant, but the specific terms or amount are not detailed in the provided text.
When did the unregistered sales of equity securities occur?
The filing mentions unregistered sales of equity securities as an item of information, but the specific date or details of these sales are not provided in the summary text.
What is the company's state of incorporation and fiscal year end?
Propanc Biopharma, Inc. is incorporated in Delaware and its fiscal year ends on June 30.
What are the business and mailing addresses for Propanc Biopharma?
The business and mailing addresses for Propanc Biopharma are listed as 302/6 Butler Street, Camberwell, VIC, 3124, Australia.
Filing Stats: 1,092 words · 4 min read · ~4 pages · Grade level 12.1 · Accepted 2024-08-14 20:31:24
Key Financial Figures
- $33,000 — ny in the aggregate principal amount of $33,000 (the "Note"), for a purchase price of $
- $30,000 — 0 (the "Note"), for a purchase price of $30,000. The Company intends to use the net pro
- $0.0017 — tock at a price ("Conversion Price") of $0.0017 per share (the "Fixed Price"). Provided
- $0.0014 — the Company's Common Stock trades below $0.0014 per share for more than five (5) consec
- $0.001 — then the Fixed Price shall be equal to $0.001 per share. In the Event of Default (as
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex4-1.htm (EX-4.1) — 66KB
- ex10-1.htm (EX-10.1) — 79KB
- 0001493152-24-032469.txt ( ) — 388KB
- ppcb-20240809.xsd (EX-101.SCH) — 3KB
- ppcb-20240809_lab.xml (EX-101.LAB) — 33KB
- ppcb-20240809_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 14, 2024 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer and Chief Financial Officer